Drug Patents Expiring in 2024

1. List of Abilify drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8017615 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Jun, 2024

(1 year, 4 months from now)

US7115587 OTSUKA Aripiprazole complex formulation and method
Jul, 2024

(1 year, 5 months from now)

US7550445 OTSUKA Aripiprazole complex formulation and method
Jul, 2024

(1 year, 5 months from now)

US8017615

(Pediatric)

OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Dec, 2024

(1 year, 10 months from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 07 June, 2006

Treatment: Treatment of schizophrenia

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

How can I launch a generic of ABILIFY before it's patent expiration?
More Information on Dosage

2. List of Abilify Maintena Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8030313 OTSUKA PHARM CO LTD Controlled release sterile injectable aripiprazole formulation and method
Oct, 2024

(1 year, 8 months from now)

US8722679 OTSUKA PHARM CO LTD Controlled release sterile injectable aripiprazole formulation and method
Oct, 2024

(1 year, 8 months from now)

US7807680 OTSUKA PHARM CO LTD Controlled release sterile injectable aripiprazole formulation and method
Oct, 2024

(1 year, 8 months from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 28 February, 2013

Treatment: Treatment of schizophrenia; Treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

How can I launch a generic of ABILIFY MAINTENA KIT before it's patent expiration?
More Information on Dosage

3. List of Abilify Mycite Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8017615 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Jun, 2024

(1 year, 4 months from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 13 November, 2017

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

4. List of Abraxane drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7923536

(Pediatric)

ABRAXIS BIOSCIENCE Compositions and methods of delivery of pharmacological agents
Jun, 2024

(1 year, 4 months from now)

US8314156

(Pediatric)

ABRAXIS BIOSCIENCE Compositions and methods of delivery of pharmacological agents
Jun, 2024

(1 year, 4 months from now)

US8138229

(Pediatric)

ABRAXIS BIOSCIENCE Compositions and methods of delivery of pharmacological agents
Jun, 2024

(1 year, 4 months from now)

US7820788 ABRAXIS BIOSCIENCE Compositions and methods of delivery of pharmacological agents
Oct, 2024

(1 year, 8 months from now)

Exclusivity Exclusivity Expiration
M Dec 6, 2022
Pediatric Exclusivity (PED) Jun 6, 2023

Drugs and Companies using PACLITAXEL ingredient

Market Authorisation Date: 07 January, 2005

Treatment: Treatment of lung cancer; Treatment of breast cancer; Treatment of pancreatic cancer

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of ABRAXANE before it's patent expiration?
More Information on Dosage

5. List of Acular Ls drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8377982 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(1 year, 3 months from now)

US8207215 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(1 year, 3 months from now)

US8906950 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(1 year, 3 months from now)

US8946281 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(1 year, 3 months from now)

US8648107 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(1 year, 3 months from now)

US9216167 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(1 year, 3 months from now)

US8541463 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(1 year, 3 months from now)

US8377982

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
Nov, 2024

(1 year, 9 months from now)

US8207215

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
Nov, 2024

(1 year, 9 months from now)

US8541463

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
Nov, 2024

(1 year, 9 months from now)

Drugs and Companies using KETOROLAC TROMETHAMINE ingredient

Market Authorisation Date: 30 May, 2003

Treatment: A method of treating or preventing ocular pain and burning/stinging following corneal surgery; A method of controlling postoperative ocular pain and burning/stinging in a patient; A method of treating or preventing ocular pain and burning; A method of treating ocular pain; A method of treating ocular pain and/or enhancing ocular comfort; A method of treating or reducing ocular pain and burning/stinging

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ACULAR LS before it's patent expiration?
More Information on Dosage

6. List of Acuvail drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8992952 ALLERGAN Compositions for delivery of therapeutics into the eyes and methods for making and using same
Aug, 2024

(1 year, 6 months from now)

Drugs and Companies using KETOROLAC TROMETHAMINE ingredient

Market Authorisation Date: 22 July, 2009

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ACUVAIL before it's patent expiration?
More Information on Dosage

7. List of Adasuve drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9370629 ALEXZA PHARMS Self-contained heating unit and drug-supply unit employing same
May, 2024

(1 year, 3 months from now)

US8991387 ALEXZA PHARMS Self-contained heating unit and drug-supply unit employing same
May, 2024

(1 year, 3 months from now)

US7458374 ALEXZA PHARMS Method and apparatus for vaporizing a compound
Aug, 2024

(1 year, 6 months from now)

US7537009 ALEXZA PHARMS Method of forming an aerosol for inhalation delivery
Oct, 2024

(1 year, 8 months from now)

Drugs and Companies using LOXAPINE ingredient

Market Authorisation Date: 21 December, 2012

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

8. List of Airduo Digihaler drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9987229 TEVA PHARM Process for preparing a medicament
Sep, 2024

(1 year, 6 months from now)

US9616024 TEVA PHARM Process for preparing a medicament
Sep, 2024

(1 year, 6 months from now)

Exclusivity Exclusivity Expiration
M Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

9. List of Aldara drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7696159 BAUSCH Treatment for basal cell carcinoma
Apr, 2024

(1 year, 1 month from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7696159

(Pediatric)

BAUSCH Treatment for basal cell carcinoma
Oct, 2024

(1 year, 7 months from now)

Drugs and Companies using IMIQUIMOD ingredient

Market Authorisation Date: 27 February, 1997

Treatment: Treatment of biopsy-confirmed, primary superficial basal cell carcinoma (sbcc); Works through the induction of interferon and other cytokines

Dosage: CREAM;TOPICAL

How can I launch a generic of ALDARA before it's patent expiration?
More Information on Dosage

10. List of Aliqopa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7511041 BAYER HEALTHCARE Fused azole-pyrimidine derivatives
May, 2024

(1 year, 3 months from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 14, 2022
Orphan Drug Exclusivity (ODE) Sep 14, 2024

Drugs and Companies using COPANLISIB DIHYDROCHLORIDE ingredient

NCE-1 date: September, 2021

Market Authorisation Date: 14 September, 2017

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

11. List of Aloxi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7947724 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(11 months from now)

US9066980 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(11 months from now)

US8729094 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(11 months from now)

US9457020 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(11 months from now)

US8518981 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(11 months from now)

US9439854 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(11 months from now)

US7947725 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(11 months from now)

US8598218 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(11 months from now)

US9457021 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(11 months from now)

US9125905 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(11 months from now)

US7960424 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(11 months from now)

US9173942 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(11 months from now)

US8598219 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jan, 2024

(11 months from now)

US8598218

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(1 year, 5 months from now)

US9066980

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(1 year, 5 months from now)

US9457021

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(1 year, 5 months from now)

US9125905

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(1 year, 5 months from now)

US8598219

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(1 year, 5 months from now)

US8729094

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(1 year, 5 months from now)

US9457020

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(1 year, 5 months from now)

US9439854

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(1 year, 5 months from now)

US9173942

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(1 year, 5 months from now)

US7947725

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(1 year, 5 months from now)

US7947724

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(1 year, 5 months from now)

US8518981

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(1 year, 5 months from now)

US7960424

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(1 year, 5 months from now)

Drugs and Companies using PALONOSETRON HYDROCHLORIDE ingredient

Market Authorisation Date: 25 July, 2003

Treatment: Prevention of chemotherapy-induced nausea and vomiting

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of ALOXI before it's patent expiration?
More Information on Dosage

12. List of Alphagan P drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8858961

(Pediatric)

ALLERGAN Compositions containing alpha-2-adrenergic agonist components
Mar, 2024

(1 year, 30 days from now)

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Market Authorisation Date: 19 August, 2005

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ALPHAGAN P before it's patent expiration?
More Information on Dosage

13. List of Altabax drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8207191 ALMIRALL Process, salts, composition and use
Aug, 2024

(1 year, 6 months from now)

Drugs and Companies using RETAPAMULIN ingredient

Market Authorisation Date: 12 April, 2007

Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes

Dosage: OINTMENT;TOPICAL

More Information on Dosage

14. List of Amitiza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7795312 SUCAMPO PHARMA LLC Method for treating abdominal discomfort
Sep, 2024

(1 year, 7 months from now)

Drugs and Companies using LUBIPROSTONE ingredient

Market Authorisation Date: 31 January, 2006

Treatment: Method for treating irritable bowel syndrome and method for treating abdominal discomfort associated with irritable bowel syndrome

Dosage: CAPSULE;ORAL

How can I launch a generic of AMITIZA before it's patent expiration?
More Information on Dosage

15. List of Anjeso drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10471067 BAUDAX Nanoparticulate meloxicam formulations
Feb, 2024

(1 year, 23 days from now)

US10463673 BAUDAX Nanoparticulate meloxicam formulations
Feb, 2024

(1 year, 23 days from now)

Exclusivity Exclusivity Expiration
New Product (NP) Feb 20, 2023

Drugs and Companies using MELOXICAM ingredient

Market Authorisation Date: 20 February, 2020

Treatment: Management of moderate-to-severe pain by intravenous injection

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

16. List of Arikayce Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9827317 INSMED INC Sustained release of antiinfectives
Apr, 2024

(1 year, 2 months from now)

US8802137 INSMED INC Sustained release of antiinfectives
Apr, 2024

(1 year, 2 months from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 28, 2025
Generating Antibiotic Incentives Now (GAIN) Sep 28, 2030

Drugs and Companies using AMIKACIN SULFATE ingredient

Market Authorisation Date: 28 September, 2018

Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination antibacterial drug regimen; Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination drug regimen

Dosage: SUSPENSION, LIPOSOMAL;INHALATION

More Information on Dosage

17. List of Armonair Digihaler drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9616024 TEVA PHARM Process for preparing a medicament
Sep, 2024

(1 year, 6 months from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jul 9, 2024
New Strength (NS) Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

18. List of Atripla drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8592397 GILEAD SCIENCES Compositions and methods for combination antiviral therapy
Jan, 2024

(11 months from now)

US8716264 GILEAD SCIENCES Compositions and methods for combination antiviral therapy
Jan, 2024

(11 months from now)

US9744181 GILEAD SCIENCES Compositions and methods for combination antiviral therapy
Jan, 2024

(11 months from now)

US9457036 GILEAD SCIENCES Compositions and methods for combination antiviral therapy
Jan, 2024

(11 months from now)

Drugs and Companies using EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

Market Authorisation Date: 12 July, 2006

Treatment: Treatment of hiv-1 infection in pediatric patients 12 years of age and older; Treatment of hiv-1 infection in adults; Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of ATRIPLA before it's patent expiration?
More Information on Dosage

19. List of Auryxia drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7767851 KERYX BIOPHARMS Ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(1 year, 17 days from now)

US8338642 KERYX BIOPHARMS Ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(1 year, 17 days from now)

US9757416 KERYX BIOPHARMS Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(1 year, 17 days from now)

US9328133 KERYX BIOPHARMS Ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(1 year, 17 days from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9050316 KERYX BIOPHARMS Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(1 year, 17 days from now)

US8754257 KERYX BIOPHARMS Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(1 year, 17 days from now)

US8609896 KERYX BIOPHARMS Ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(1 year, 17 days from now)

US8299298 KERYX BIOPHARMS Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
Feb, 2024

(1 year, 17 days from now)

US8754258 KERYX BIOPHARMS Ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(1 year, 17 days from now)

US8901349 KERYX BIOPHARMS Ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(1 year, 17 days from now)

US8846976 KERYX BIOPHARMS Ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(1 year, 17 days from now)

Drugs and Companies using FERRIC CITRATE ingredient

Market Authorisation Date: 05 September, 2014

Treatment: Control of serum phosphorous levels

Dosage: TABLET;ORAL

More Information on Dosage

20. List of Auvi-q drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10314977 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

US9737669 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

US8920377 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

US8361029 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

US9056170 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

US8313466 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

US8608698 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

US7918823 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

US10737028 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

US8425462 KALEO INC Devices, systems, and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

US9833573 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 10 August, 2012

Treatment: Method to treat severe allergic emergencies in patients weighing 7.5 to 15 kg (16.5 to 33 lbs)

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

21. List of Bosulif drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE42376 PF PRISM CV Substituted 3-cyanoquinolines
Apr, 2024

(1 year, 2 months from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 19, 2024

Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient

Market Authorisation Date: 04 September, 2012

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of BOSULIF before it's patent expiration?
More Information on Dosage

22. List of Brilinta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46276 ASTRAZENECA Triazolo(4,5-D)pyrimidine compounds
Oct, 2024

(1 year, 8 months from now)

Exclusivity Exclusivity Expiration
New Indication (I) Nov 5, 2023
M May 9, 2025
Pediatric Exclusivity (PED) Nov 28, 2023

Drugs and Companies using TICAGRELOR ingredient

Market Authorisation Date: 20 July, 2011

Treatment: Treatment of myocardial infarction and stroke in patients with acute coronary syndrome or a history of myocardial infarction; Reduction of the rate of cardiovascular death, myocardial infarction, and stroke in patients with a history of myocardial infarction; Treatment of stroke in patients with acute coronary syndrome or a history of myocardial infarction; Treatment of myocardial infarction in patients with acute coronary syndrome or a history of myocardial infarction; Reduction of the risk of stroke in patients with acute ischemic stroke or high-risk transient ischemic attack; Treatment of myocardial infarction or stroke in patients with coronary artery disease at high risk for such events; Reduction of the rate of a first myocardial infarction or stroke in patients with coronary artery disease at high risk for such events

Dosage: TABLET;ORAL

How can I launch a generic of BRILINTA before it's patent expiration?
More Information on Dosage

23. List of Bydureon drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7563871 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2024

(1 year, 2 months from now)

US9238076 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2024

(1 year, 2 months from now)

US9238076

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2024

(1 year, 8 months from now)

US7563871

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2024

(1 year, 8 months from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jul 22, 2024
M Feb 15, 2022
Pediatric Exclusivity (PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; Improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation as an adjunct to diet and exercise to provide a release profile having a ratio of c-max to c-avg of about 3 or less; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; Improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

24. List of Bydureon Bcise drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238076 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2024

(1 year, 2 months from now)

US7563871 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2024

(1 year, 2 months from now)

US7563871

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2024

(1 year, 8 months from now)

US9238076

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2024

(1 year, 8 months from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jul 22, 2024
M Feb 15, 2022
Pediatric Exclusivity (PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 20 October, 2017

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; Improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation as an adjunct to diet and exercise to provide a release profile having a ratio of c-max to c-avg of about 3 or less; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin as add-on to metformin; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; Improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication

Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

25. List of Cabometyx drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8497284 EXELIXIS INC C-met modulators and method of use
Sep, 2024

(1 year, 7 months from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 17, 2028
New Indication (I) Sep 17, 2024

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Market Authorisation Date: 25 April, 2016

Treatment: Treatment of renal cell carcinoma; Treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib; Treatment of advanced renal cell carcinoma

Dosage: TABLET;ORAL

How can I launch a generic of CABOMETYX before it's patent expiration?
More Information on Dosage

26. List of Children's Advil drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10238640 GLAXOSMITHKLINE Pharmaceutical suspension composition
May, 2024

(1 year, 3 months from now)

Drugs and Companies using IBUPROFEN ingredient

Market Authorisation Date: 27 June, 1996

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage

27. List of Children's Advil Allergy Sinus drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10238640 GLAXOSMITHKLINE Pharmaceutical suspension composition
May, 2024

(1 year, 3 months from now)

Drugs and Companies using CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 February, 2004

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage

28. List of Chloraprep One-step drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6991394 BECTON DICKINSON CO Liquid applicator with a mechanism for fracturing multiple ampoules
Jan, 2024

(11 months from now)

Drugs and Companies using CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL ingredient

Market Authorisation Date: 14 July, 2000

Treatment: NA

Dosage: SPONGE;TOPICAL

More Information on Dosage

29. List of Chlorhexidine Gluconate drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7066916 SAGE PRODS Disinfectant delivery system, and method of providing alcohol-free disinfection
Feb, 2024

(1 year, 16 days from now)

Drugs and Companies using CHLORHEXIDINE GLUCONATE ingredient

Market Authorisation Date: 25 April, 2005

Treatment: Disinfection of patient skin prior to an invasive procedure

Dosage: CLOTH;TOPICAL

More Information on Dosage

30. List of Combivent Respimat drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7284474 BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties
Aug, 2024

(1 year, 6 months from now)

Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient

Market Authorisation Date: 07 October, 2011

Treatment: NA

Dosage: SPRAY, METERED;INHALATION

More Information on Dosage

31. List of Complera drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8716264 GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy
Jan, 2024

(11 months from now)

US9457036 GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy
Jan, 2024

(11 months from now)

US8592397 GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy
Jan, 2024

(11 months from now)

US9744181 GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy
Jan, 2024

(11 months from now)

Drugs and Companies using EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE ingredient

Market Authorisation Date: 10 August, 2011

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of COMPLERA before it's patent expiration?
More Information on Dosage

32. List of Contrave drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11278544 NALPROPION Compositions for affecting weight loss
Apr, 2024

(1 year, 2 months from now)

US7462626 NALPROPION Compositions for affecting weight loss
Jul, 2024

(1 year, 5 months from now)

US8815889 NALPROPION Compositions and methods for increasing insulin sensitivity
Jul, 2024

(1 year, 5 months from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 10 September, 2014

Treatment: For chronic weight management for treating overweight or obesity; For effect on blood glucose parameters in patients with insulin resistance

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of CONTRAVE before it's patent expiration?
More Information on Dosage

33. List of Daliresp drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8618142 ASTRAZENECA Process for the preparation of roflumilast
Mar, 2024

(1 year, 1 month from now)

US8536206 ASTRAZENECA Process for the preparation of roflumilast
Mar, 2024

(1 year, 1 month from now)

US8604064 ASTRAZENECA Process for the preparation of roflumilast
Mar, 2024

(1 year, 1 month from now)

Drugs and Companies using ROFLUMILAST ingredient

Market Authorisation Date: 28 February, 2011

Treatment: Treatment to reduce the risk of copd exacerbations in patients with severe copd associated with chronic bronchitis and a history of exacerbations

Dosage: TABLET;ORAL

How can I launch a generic of DALIRESP before it's patent expiration?
More Information on Dosage

34. List of Dexilant drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8722084

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Apr, 2024

(1 year, 2 months from now)

US8784885

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Apr, 2024

(1 year, 2 months from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 30 January, 2009

Treatment: NA

Dosage: CAPSULE, DELAYED RELEASE;ORAL

How can I launch a generic of DEXILANT before it's patent expiration?
More Information on Dosage

35. List of Dexilant Solutab drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8784885

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Apr, 2024

(1 year, 2 months from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 26 January, 2016

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

More Information on Dosage

36. List of Dextenza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9254267 OCULAR THERAPEUTIX Composite hydrogel drug delivery systems
Sep, 2024

(1 year, 7 months from now)

Exclusivity Exclusivity Expiration
New Indication (I) Oct 7, 2024

Drugs and Companies using DEXAMETHASONE ingredient

Market Authorisation Date: 30 November, 2018

Treatment: NA

Dosage: INSERT;OPHTHALMIC

More Information on Dosage

37. List of Differin drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7737181 GALDERMA LABS LP Pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
Aug, 2024

(1 year, 6 months from now)

Drugs and Companies using ADAPALENE ingredient

Market Authorisation Date: 19 June, 2007

Treatment: NA

Dosage: GEL;TOPICAL

How can I launch a generic of DIFFERIN before it's patent expiration?
More Information on Dosage

38. List of Dificid drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8586551

(Pediatric)

CUBIST PHARMS LLC 18-membered macrocycles and analogs thereof
Jan, 2024

(11 months from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jan 24, 2023
Orphan Drug Exclusivity (ODE) Jan 24, 2027
Pediatric Exclusivity (PED) Jul 24, 2023

Drugs and Companies using FIDAXOMICIN ingredient

Market Authorisation Date: 27 May, 2011

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of DIFICID before it's patent expiration?
More Information on Dosage

39. List of Diprivan drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8476010 FRESENIUS KABI USA Propofol formulations with non-reactive container closures
Dec, 2024

(1 year, 9 months from now)

Drugs and Companies using PROPOFOL ingredient

Market Authorisation Date: 02 October, 1989

Treatment: NA

Dosage: INJECTABLE;INJECTION

How can I launch a generic of DIPRIVAN before it's patent expiration?
More Information on Dosage

40. List of Duavee drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6479535 WYETH PHARMS 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
May, 2024

(1 year, 3 months from now)

Drugs and Companies using BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED ingredient

Market Authorisation Date: 03 October, 2013

Treatment: Prevention of postmenopausal osteoporosis; Treatment of moderate to severe vasomotor symptoms associated with menopause

Dosage: TABLET;ORAL

More Information on Dosage

41. List of Durysta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10398707 ALLERGAN INC Hypotensive lipid-containing biodegradable intraocular implants and related implants
Apr, 2024

(1 year, 2 months from now)

Exclusivity Exclusivity Expiration
New Product (NP) Mar 4, 2023

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 04 March, 2020

Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant

Dosage: IMPLANT;OPHTHALMIC

More Information on Dosage

42. List of Dutrebis drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7169780

(Pediatric)

MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2024

(1 year, 2 months from now)

Drugs and Companies using LAMIVUDINE; RALTEGRAVIR POTASSIUM ingredient

Market Authorisation Date: 06 February, 2015

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

43. List of Dymista drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8163723

(Pediatric)

MYLAN SPECIALITY LP Combination of azelastine and steroids
Feb, 2024

(1 year, 28 days from now)

Drugs and Companies using AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 01 May, 2012

Treatment: NA

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of DYMISTA before it's patent expiration?
More Information on Dosage

44. List of Entresto drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7468390

(Pediatric)

NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition
May, 2024

(1 year, 3 months from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Oct 1, 2022
M Feb 16, 2024
Pediatric Exclusivity (PED) Apr 1, 2023

Drugs and Companies using SACUBITRIL; VALSARTAN ingredient

Market Authorisation Date: 07 July, 2015

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ENTRESTO before it's patent expiration?
More Information on Dosage

45. List of Envarsus Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11077096 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(1 year, 6 months from now)

US8889186 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(1 year, 6 months from now)

US8623411 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(1 year, 6 months from now)

US8889185 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(1 year, 6 months from now)

US8586084 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(1 year, 6 months from now)

US8486993 VELOXIS PHARMS INC Solid dispersions comprising tacrolimus
Aug, 2024

(1 year, 6 months from now)

US9161907 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(1 year, 6 months from now)

US10548880 VELOXIS PHARMS INC Solid dispersions comprising tacrolimus
Aug, 2024

(1 year, 6 months from now)

US9757362 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(1 year, 6 months from now)

US8617599 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(1 year, 6 months from now)

US8623410 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(1 year, 6 months from now)

US9763920 VELOXIS PHARMS INC Solid dispersions comprising tacrolimus
Aug, 2024

(1 year, 6 months from now)

US8591946 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(1 year, 6 months from now)

US7994214 VELOXIS PHARMS INC Solid dispersions comprising tacrolimus
Aug, 2024

(1 year, 6 months from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jul 10, 2022

Drugs and Companies using TACROLIMUS ingredient

Market Authorisation Date: 10 July, 2015

Treatment: Prophylaxis of organ rejection; Prophylaxis of organ rejection in patients converted from tacrolimus immediate-release formulations; Prophylaxis of organ rejection in de novo transplant patient

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of ENVARSUS XR before it's patent expiration?
More Information on Dosage

46. List of Epiduo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7964202 GALDERMA LABS LP Method for treatment of common acne
Sep, 2024

(1 year, 6 months from now)

Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE ingredient

Market Authorisation Date: 08 December, 2008

Treatment: Treatment of acne

Dosage: GEL;TOPICAL

How can I launch a generic of EPIDUO before it's patent expiration?
More Information on Dosage

47. List of Equetro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6977253 VALIDUS PHARMS Methods for the treatment of bipolar disorder using carbamazepine
May, 2024

(1 year, 3 months from now)

Drugs and Companies using CARBAMAZEPINE ingredient

Market Authorisation Date: 10 December, 2004

Treatment: The recommended initial dose of equetro is 400mg/day given in divided doses, twice daily. the dose should be adjusted in 200mg daily increments to achieve optimal clinical response.

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of EQUETRO before it's patent expiration?
More Information on Dosage

48. List of Evekeo Odt drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10130580 ARBOR PHARMS LLC Taste-masked pharmaceutical compositions
Apr, 2024

(1 year, 2 months from now)

Drugs and Companies using AMPHETAMINE SULFATE ingredient

Market Authorisation Date: 30 January, 2019

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage

49. List of Evoclin drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7374747 MYLAN Pharmaceutical foam
Jan, 2024

(11 months from now)

US7141237 MYLAN Pharmaceutical foam
Feb, 2024

(1 year, 2 days from now)

Drugs and Companies using CLINDAMYCIN PHOSPHATE ingredient

Market Authorisation Date: 22 October, 2004

Treatment: Treatment of acne vulgaris

Dosage: AEROSOL, FOAM;TOPICAL

How can I launch a generic of EVOCLIN before it's patent expiration?
More Information on Dosage

50. List of Evzio drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10737028 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

US9737669 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

US9056170 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

US8361029 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

US8608698 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

US8313466 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

US7918823 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

US8425462 KALEO INC Devices, systems, and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

US10314977 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 03 April, 2014

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

51. List of Evzio (autoinjector) drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8608698 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

US8425462 KALEO INC Devices, systems, and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

US9737669 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

US10314977 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

US10737028 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

US7918823 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

US8361029 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

US9056170 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

US8313466 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 October, 2016

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

52. List of Exservan drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8765167 MITSUBISHI HOLDINGS Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
Feb, 2024

(1 year, 19 days from now)

US8603514 MITSUBISHI HOLDINGS Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
Apr, 2024

(1 year, 2 months from now)

Drugs and Companies using RILUZOLE ingredient

Market Authorisation Date: 22 November, 2019

Treatment: NA

Dosage: FILM;ORAL

More Information on Dosage

53. List of Farxiga drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238076 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2024

(1 year, 2 months from now)

Exclusivity Exclusivity Expiration
M Feb 22, 2022
New Indication (I) Oct 18, 2022

Drugs and Companies using DAPAGLIFLOZIN ingredient

Market Authorisation Date: 08 January, 2014

Treatment: Treatment of type 2 diabetes mellitus in combination with exenatide

Dosage: TABLET;ORAL

How can I launch a generic of FARXIGA before it's patent expiration?
More Information on Dosage

54. List of Fenoglide drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8481078 SALIX Solid dosage form comprising a fibrate
Oct, 2024

(1 year, 7 months from now)

US8124125 SALIX Solid dosage form comprising a fibrate
Oct, 2024

(1 year, 7 months from now)

US9173847 SALIX Tablet comprising a fibrate
Oct, 2024

(1 year, 7 months from now)

US7658944 SALIX Solid dosage form comprising a fibrate
Dec, 2024

(1 year, 10 months from now)

Drugs and Companies using FENOFIBRATE ingredient

Market Authorisation Date: 10 August, 2007

Treatment: Use of fenofibrate for reducing elevated total cholesterol (total-c), ldl-c, apo-lipoprotein b, or total triglycerides; For reducing total cholesterol (total-c), ldl-c, apo-lipoprotein b, or total triglycerides, and treating hypertriglyceridemia

Dosage: TABLET;ORAL

How can I launch a generic of FENOGLIDE before it's patent expiration?
More Information on Dosage

55. List of Fentora drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8119158 CEPHALON Effervescent oral fentanyl dosage form and methods of administering fentanyl
Dec, 2024

(1 year, 10 months from now)

US8092832 CEPHALON Generally linear effervescent oral fentanyl dosage form and methods of administering
Dec, 2024

(1 year, 10 months from now)

Drugs and Companies using FENTANYL CITRATE ingredient

Market Authorisation Date: 25 September, 2006

Treatment: NA

Dosage: TABLET;BUCCAL, SUBLINGUAL

How can I launch a generic of FENTORA before it's patent expiration?
More Information on Dosage

56. List of Finacea drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8435498 LEO PHARMA AS Penetrating pharmaceutical foam
Mar, 2024

(1 year, 29 days from now)

Drugs and Companies using AZELAIC ACID ingredient

Market Authorisation Date: 29 July, 2015

Treatment: Topical treatment of inflammatory papules and pustules of mild to moderate rosacea

Dosage: AEROSOL, FOAM;TOPICAL

How can I launch a generic of FINACEA before it's patent expiration?
More Information on Dosage

57. List of Flonase Sensimist Allergy Relief drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9320862 GLAXOSMITHKLINE CONS Fluid dispensing device
Nov, 2024

(1 year, 9 months from now)

Drugs and Companies using FLUTICASONE FUROATE ingredient

Market Authorisation Date: 02 August, 2016

Treatment: NA

Dosage: SPRAY, METERED;NASAL

More Information on Dosage

58. List of Fosrenol drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7465465 TAKEDA PHARMS USA Pharmaceutical formulation comprising lanthanum compounds
Aug, 2024

(1 year, 6 months from now)

US7381428 TAKEDA PHARMS USA Stabilized lanthanum carbonate compositions
Aug, 2024

(1 year, 6 months from now)

Drugs and Companies using LANTHANUM CARBONATE ingredient

Market Authorisation Date: 26 October, 2004

Treatment: Reduction of serum phosphate in patients with end stage renal disease

Dosage: TABLET, CHEWABLE;ORAL

How can I launch a generic of FOSRENOL before it's patent expiration?
More Information on Dosage

59. List of Givlaari drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9708610 ALNYLAM PHARMS INC Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Jan, 2024

(10 months from now)

US10273477 ALNYLAM PHARMS INC Therapeutic compositions
Mar, 2024

(1 year, 1 month from now)

US9708615 ALNYLAM PHARMS INC Therapeutic compositions
Mar, 2024

(1 year, 1 month from now)

US11530408 ALNYLAM PHARMS INC Therapeutic compositions
May, 2024

(1 year, 3 months from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 20, 2024
Orphan Drug Exclusivity (ODE) Nov 20, 2026

Drugs and Companies using GIVOSIRAN SODIUM ingredient

NCE-1 date: November, 2023

Market Authorisation Date: 20 November, 2019

Treatment: Treatment of acute hepatic porphyria

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

60. List of Gralise drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7438927 ALMATICA Methods of treatment using a gastric retained gabapentin dosage
Feb, 2024

(1 year, 25 days from now)

Drugs and Companies using GABAPENTIN ingredient

Market Authorisation Date: 28 January, 2011

Treatment: Treatment with gabapentin, including treatment of neuropathic pain, including neuropathic pain associated with postherpetic neuralgia

Dosage: TABLET;ORAL

How can I launch a generic of GRALISE before it's patent expiration?
More Information on Dosage

61. List of Halaven drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6214865

(Pediatric)

EISAI INC Macrocyclic analogs and methods of their use and preparation
Jan, 2024

(11 months from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jan 28, 2023
M Sep 13, 2025
Pediatric Exclusivity (PED) Mar 13, 2026

Drugs and Companies using ERIBULIN MESYLATE ingredient

Market Authorisation Date: 15 November, 2010

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of HALAVEN before it's patent expiration?
More Information on Dosage

62. List of Hycamtin drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8158645 NOVARTIS Compound, corresponding compositions, preparation and/or treatment methods
Dec, 2024

(1 year, 10 months from now)

Drugs and Companies using TOPOTECAN HYDROCHLORIDE ingredient

Market Authorisation Date: 11 October, 2007

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

63. List of Ilevro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7947295 NOVARTIS Ophthalmic compositions containing a synergistic combination of two polymers
Jun, 2024

(1 year, 4 months from now)

Drugs and Companies using NEPAFENAC ingredient

Market Authorisation Date: 16 October, 2012

Treatment: NA

Dosage: SUSPENSION/DROPS;OPHTHALMIC

How can I launch a generic of ILEVRO before it's patent expiration?
More Information on Dosage

64. List of Inbrija drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7182961 ACORDA Particulate compositions for pulmonary delivery
Feb, 2024

(1 year, 21 days from now)

Drugs and Companies using LEVODOPA ingredient

Market Authorisation Date: 21 December, 2018

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

65. List of Injectafer drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7612109 AM REGENT Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes
Feb, 2024

(1 year, 4 days from now)

Exclusivity Exclusivity Expiration
New Strength (NS) Apr 28, 2024
New Patient Population (NPP) Nov 19, 2024

Drugs and Companies using FERRIC CARBOXYMALTOSE ingredient

Market Authorisation Date: 25 July, 2013

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of INJECTAFER before it's patent expiration?
More Information on Dosage

66. List of Invokamet drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8785403 JANSSEN PHARMS Glucopyranoside compound
Jul, 2024

(1 year, 5 months from now)

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 08 August, 2014

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of INVOKAMET before it's patent expiration?
More Information on Dosage

67. List of Invokamet Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8785403 JANSSEN PHARMS Glucopyranoside compound
Jul, 2024

(1 year, 5 months from now)

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 20 September, 2016

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of INVOKAMET XR before it's patent expiration?
More Information on Dosage

68. List of Ionsys drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6975902 THE MEDICINES CO Reservoir and a series of related reservoirs for use in an electrotransport drug delivery device and devices comprised thereof
Apr, 2024

(1 year, 1 month from now)

Drugs and Companies using FENTANYL HYDROCHLORIDE ingredient

Market Authorisation Date: 22 May, 2006

Treatment: NA

Dosage: SYSTEM;IONTOPHORESIS, TRANSDERMAL

More Information on Dosage

69. List of Isentress drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7169780

(Pediatric)

MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2024

(1 year, 2 months from now)

Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient

Market Authorisation Date: 12 October, 2007

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ISENTRESS before it's patent expiration?
More Information on Dosage

70. List of Ixempra Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7312237 R-PHARM US LLC Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases
Aug, 2024

(1 year, 6 months from now)

Drugs and Companies using IXABEPILONE ingredient

Market Authorisation Date: 16 October, 2007

Treatment: Use of ixabepilone in combination with capecitabine in treatment of metastasis breast cancer

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of IXEMPRA KIT before it's patent expiration?
More Information on Dosage

71. List of Koselugo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7425637 ASTRAZENECA N3 alkylated benzimidazole derivatives as MEK inhibitors
Apr, 2024

(1 year, 2 months from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 10, 2025
Orphan Drug Exclusivity (ODE) Apr 10, 2027

Drugs and Companies using SELUMETINIB SULFATE ingredient

NCE-1 date: April, 2024

Market Authorisation Date: 10 April, 2020

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

72. List of Kuvan drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE43797 BIOMARIN PHARM Methods of administering tetrahydrobiopterin
Nov, 2024

(1 year, 9 months from now)

US7612073 BIOMARIN PHARM Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
Nov, 2024

(1 year, 9 months from now)

US9433624 BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders
Nov, 2024

(1 year, 9 months from now)

US7566714 BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders
Nov, 2024

(1 year, 9 months from now)

US8067416 BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders
Nov, 2024

(1 year, 9 months from now)

US8318745 BIOMARIN PHARM Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride
Nov, 2024

(1 year, 9 months from now)

US7727987 BIOMARIN PHARM Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride
Nov, 2024

(1 year, 9 months from now)

Drugs and Companies using SAPROPTERIN DIHYDROCHLORIDE ingredient

Market Authorisation Date: 13 December, 2007

Treatment: Kuvan is indicated to reduce blood phenylalanine levels in patients with hyperphenylalaninemia; To reduce blood phenylalanine levels in patients with hyperphenylalaninemia due to tetra hydrobiopterin responsive phenylketonuria. kuvan should be taken orally with food to increase absorption; Method of use for reducing blood phenylalanine levels in a human suffering from hyperphenylalaninemia; For reducing blood phenylalanine levels in a human suffering from hyperphenylalaninemia

Dosage: TABLET;ORAL

How can I launch a generic of KUVAN before it's patent expiration?
More Information on Dosage

73. List of Kynmobi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8765167 SUNOVION PHARMS INC Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
Feb, 2024

(1 year, 19 days from now)

US8603514 SUNOVION PHARMS INC Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
Apr, 2024

(1 year, 2 months from now)

Exclusivity Exclusivity Expiration
New Product (NP) May 21, 2023

Drugs and Companies using APOMORPHINE HYDROCHLORIDE ingredient

Market Authorisation Date: 21 May, 2020

Treatment: NA

Dosage: FILM;SUBLINGUAL

More Information on Dosage

74. List of Latisse drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101161 ALLERGAN Method of enhancing hair growth
May, 2024

(1 year, 3 months from now)

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 24 December, 2008

Treatment: Method of stimulating hair growth; Method of increasing hair growth

Dosage: SOLUTION/DROPS;TOPICAL

How can I launch a generic of LATISSE before it's patent expiration?
More Information on Dosage

75. List of Latuda drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9174975 SUNOVION PHARMS INC Remedy for integration dysfunction syndrome
Feb, 2024

(1 year, 19 days from now)

US9815827 SUNOVION PHARMS INC Agent for treatment of schizophrenia
Feb, 2024

(1 year, 19 days from now)

US9174975

(Pediatric)

SUNOVION PHARMS INC Remedy for integration dysfunction syndrome
Aug, 2024

(1 year, 6 months from now)

Drugs and Companies using LURASIDONE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 October, 2010

Treatment: Treatment of schizophrenia with improvement in negative symptoms and/or cognitive dysfunction of schizophrenia; Treatment of major depressive episodes associated with bipolar i disorder; Treatment of schizophrenia

Dosage: TABLET;ORAL

How can I launch a generic of LATUDA before it's patent expiration?
More Information on Dosage

76. List of Lazanda drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9078814 BTCP PHARMA Intranasal spray device containing pharmaceutical composition
Jan, 2024

(11 months from now)

US9814705 BTCP PHARMA Intranasal spray device containing pharmaceutical composition
Jan, 2024

(11 months from now)

US8889176 BTCP PHARMA Method of managing or treating pain
Jan, 2024

(11 months from now)

US8216604 BTCP PHARMA Method of managing or treating pain
Oct, 2024

(1 year, 8 months from now)

Drugs and Companies using FENTANYL CITRATE ingredient

Market Authorisation Date: 30 June, 2011

Treatment: Management of breakthrough pain in patients with cancer

Dosage: SPRAY, METERED;NASAL

More Information on Dosage

77. List of Leqvio drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9708610 NOVARTIS Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Jan, 2024

(10 months from now)

US9708615 NOVARTIS Therapeutic compositions
Mar, 2024

(1 year, 1 month from now)

US10273477 NOVARTIS Therapeutic compositions
Mar, 2024

(1 year, 1 month from now)

US10669544 NOVARTIS Therapeutic compositions
Mar, 2024

(1 year, 1 month from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 22, 2026

Drugs and Companies using INCLISIRAN SODIUM ingredient

NCE-1 date: December, 2025

Market Authorisation Date: 22 December, 2021

Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascvd), by inhibiting expression of the pcsk9 gene

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

78. List of Linzess drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7745409 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(11 months from now)

US8080526 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(11 months from now)

US7704947 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(11 months from now)

US7371727 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(11 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8110553 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(11 months from now)

Drugs and Companies using LINACLOTIDE ingredient

Market Authorisation Date: 30 August, 2012

Treatment: Method of treating irritable bowel syndrome with constipation in adults; Method of treating chronic idiopathic constipation in adult patients.

Dosage: CAPSULE;ORAL

How can I launch a generic of LINZESS before it's patent expiration?
More Information on Dosage

79. List of Livalo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8557993 KOWA CO Crystalline forms of pitavastatin calcium
Feb, 2024

(1 year, 1 day from now)

US7022713 KOWA CO Hyperlipemia therapeutic agent
Feb, 2024

(1 year, 18 days from now)

US8557993

(Pediatric)

KOWA CO Crystalline forms of pitavastatin calcium
Aug, 2024

(1 year, 6 months from now)

US7022713

(Pediatric)

KOWA CO Hyperlipemia therapeutic agent
Aug, 2024

(1 year, 6 months from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) May 16, 2022
Pediatric Exclusivity (PED) Nov 16, 2022

Drugs and Companies using PITAVASTATIN CALCIUM ingredient

Market Authorisation Date: 03 August, 2009

Treatment: Adjuncitve therapy to diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein b, triglycerides and to increase hdl-c in adult patients with primary hyperlipidemia or mixed dyslipidemia

Dosage: TABLET;ORAL

How can I launch a generic of LIVALO before it's patent expiration?
More Information on Dosage

80. List of Lonhala Magnair Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7458372 SUNOVION RESP Inhalation therapy device
Nov, 2024

(1 year, 9 months from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Market Authorisation Date: 05 December, 2017

Treatment: NA

Dosage: SOLUTION;INHALATION

More Information on Dosage

81. List of Lynparza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7981889 ASTRAZENECA Phthalazinone derivatives
Oct, 2024

(1 year, 8 months from now)

US7449464 ASTRAZENECA Phthalazinone derivatives
Oct, 2024

(1 year, 8 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8912187 ASTRAZENECA Phthalazinone derivatives
Mar, 2024

(1 year, 1 month from now)

US9169235 ASTRAZENECA Phthalazinone derivatives
Mar, 2024

(1 year, 1 month from now)

US9566276 ASTRAZENECA Phthalazinone derivatives
Mar, 2024

(1 year, 1 month from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) May 8, 2027
New Indication (I) Mar 11, 2025

Drugs and Companies using OLAPARIB ingredient

Market Authorisation Date: 17 August, 2017

Treatment: Treatment of brca mutated ovarian cancer using parp inhibitor; Treatment of deleterious or suspected deleterious germline or somatic brca-mutated metastatic castration-resistant prostate cancer, which has progressed following prior treatment with enzalutamide or abiraterone; Treatment of deleterious or suspected deleterious germline or somatic homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer, which has progressed following prior treatment with enzalutamide or abiraterone; Maintenance treatment of deleterious or suspected deleterious gbrca-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen

Dosage: TABLET;ORAL

How can I launch a generic of LYNPARZA before it's patent expiration?
More Information on Dosage

82. List of Mavenclad drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7888328 EMD SERONO INC Oral formulations of cladribine
Apr, 2024

(1 year, 2 months from now)

US8785415 EMD SERONO INC Oral formulations of cladribine
Apr, 2024

(1 year, 2 months from now)

Exclusivity Exclusivity Expiration
New Product (NP) Mar 29, 2022

Drugs and Companies using CLADRIBINE ingredient

Market Authorisation Date: 29 March, 2019

Treatment: Treatment of ms with a tablet with an admixture of (a) an amorphous inclusion complex of cladribine and hydroxypropyl-b-cyclodextrin and (b) amorphous free cladribine and cyclodextrin as a non-inclusion complex, cladribine/cyclodextrin 1:10-1:16 w/w; Treatment of ms with an admixture of (a) an amorphous inclusion complex of cladribine (2cda) and cyclodextrin and (b) amorphous free 2cda and cyclodextrin as a non-inclusion complex, formulated as a solid oral form, w/o sign. amounts of cryst. 2cda

Dosage: TABLET;ORAL

How can I launch a generic of MAVENCLAD before it's patent expiration?
More Information on Dosage

83. List of Megace Es drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7101576 ENDO PHARMS INC Nanoparticulate megestrol formulations
Apr, 2024

(1 year, 2 months from now)

US9101540 ENDO PHARMS INC Nanoparticulate megestrol formulations
Apr, 2024

(1 year, 2 months from now)

US9107827 ENDO PHARMS INC Nanoparticulate megestrol formulations
Apr, 2024

(1 year, 2 months from now)

US9040088 ENDO PHARMS INC Nanoparticulate megestrol formulations
Apr, 2024

(1 year, 2 months from now)

US9101549 ENDO PHARMS INC Nanoparticulate megestrol formulations
Apr, 2024

(1 year, 2 months from now)

Drugs and Companies using MEGESTROL ACETATE ingredient

Market Authorisation Date: 05 July, 2005

Treatment: Treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids)

Dosage: SUSPENSION;ORAL

How can I launch a generic of MEGACE ES before it's patent expiration?
More Information on Dosage

84. List of Methylin drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7691880 SPECGX LLC Methylphenidate solution and associated methods of administration and production
Oct, 2024

(1 year, 8 months from now)

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 December, 2002

Treatment: NA

Dosage: SOLUTION;ORAL

How can I launch a generic of METHYLIN before it's patent expiration?
More Information on Dosage

85. List of Mirvaso drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8859551 GALDERMA LABS LP Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
May, 2024

(1 year, 3 months from now)

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Market Authorisation Date: 23 August, 2013

Treatment: Topical treatment of facial erythema of rosacea

Dosage: GEL;TOPICAL

How can I launch a generic of MIRVASO before it's patent expiration?
More Information on Dosage

86. List of Movantik drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7056500 REDHILL Polymer conjugates of opioid antagonists
Jun, 2024

(1 year, 4 months from now)

US8067431 REDHILL Chemically modified small molecules
Dec, 2024

(1 year, 10 months from now)

Drugs and Companies using NALOXEGOL OXALATE ingredient

Market Authorisation Date: 16 September, 2014

Treatment: Treatment of opioid-induced constipation

Dosage: TABLET;ORAL

How can I launch a generic of MOVANTIK before it's patent expiration?
More Information on Dosage

87. List of Moviprep drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7169381 SALIX PHARMS Colon cleansing compositions and methods
Sep, 2024

(1 year, 6 months from now)

US7658914 SALIX PHARMS Colon cleansing compositions
Sep, 2024

(1 year, 6 months from now)

How can I launch a generic of MOVIPREP before it's patent expiration?
More Information on Dosage

88. List of Mulpleta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7601746 SHIONOGI INC Compounds exhibiting thrombopoietin receptor agonism
Sep, 2024

(1 year, 7 months from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 31, 2023

Drugs and Companies using LUSUTROMBOPAG ingredient

NCE-1 date: July, 2022

Market Authorisation Date: 31 July, 2018

Treatment: Treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure

Dosage: TABLET;ORAL

More Information on Dosage

89. List of Myfembree drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8058280 MYOVANT SCIENCES Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof
Jan, 2024

(11 months from now)

US7300935 MYOVANT SCIENCES Thienopyrimidine compounds and use thereof
Jan, 2024

(11 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9346822 MYOVANT SCIENCES Thienopyrimidine compounds and use thereof
Feb, 2024

(1 year, 16 days from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 18, 2025
New Product (NP) May 26, 2024
New Indication (I) Aug 5, 2025

Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient

NCE-1 date: December, 2024

Market Authorisation Date: 26 May, 2021

Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women

Dosage: TABLET;ORAL

More Information on Dosage

90. List of Myrbetriq drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7982049

(Pediatric)

APGDI α-form or β-form crystal of acetanilide derivative
May, 2024

(1 year, 3 months from now)

US7342117

(Pediatric)

APGDI α-form or β-form crystal of acetanilide derivative
May, 2024

(1 year, 3 months from now)

USRE44872

(Pediatric)

APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
May, 2024

(1 year, 3 months from now)

US8835474

(Pediatric)

APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
May, 2024

(1 year, 3 months from now)

Exclusivity Exclusivity Expiration
New Indication (I) Mar 25, 2024
Pediatric Exclusivity (PED) Sep 25, 2024

Drugs and Companies using MIRABEGRON ingredient

Market Authorisation Date: 28 June, 2012

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of MYRBETRIQ before it's patent expiration?
More Information on Dosage

91. List of Myrbetriq Granules drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7342117

(Pediatric)

APGDI α-form or β-form crystal of acetanilide derivative
May, 2024

(1 year, 3 months from now)

US7982049

(Pediatric)

APGDI α-form or β-form crystal of acetanilide derivative
May, 2024

(1 year, 3 months from now)

Exclusivity Exclusivity Expiration
New Product (NP) Mar 25, 2024
Pediatric Exclusivity (PED) Sep 25, 2024

Drugs and Companies using MIRABEGRON ingredient

Market Authorisation Date: 25 March, 2021

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage

92. List of Naloxone Hydrochloride (autoinjector) drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10737028 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

US8313466 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

US7918823 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

US8361029 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

US9737669 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

US9056170 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

US10314977 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

US8608698 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

US8425462 KALEO INC Devices, systems, and methods for medicament delivery
Nov, 2024

(1 year, 9 months from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 February, 2022

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

93. List of Naropin drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8162915 FRESENIUS KABI USA Connector for packings containing medical liquids, and corresponding packing for medical liquids
May, 2024

(1 year, 3 months from now)

Drugs and Companies using ROPIVACAINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 September, 1996

Treatment: NA

Dosage: SOLUTION;INJECTION

How can I launch a generic of NAROPIN before it's patent expiration?
More Information on Dosage

94. List of Nascobal drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8940714 ENDO PHARMS INC Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
Feb, 2024

(1 year, 25 days from now)

US7404489 ENDO PHARMS INC Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
Mar, 2024

(1 year, 1 month from now)

US9415007 ENDO PHARMS INC Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
Jul, 2024

(1 year, 5 months from now)

US8003353 ENDO PHARMS INC Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
Aug, 2024

(1 year, 5 months from now)

US7879349 ENDO PHARMS INC Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
Aug, 2024

(1 year, 5 months from now)

US7229636 ENDO PHARMS INC Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
Aug, 2024

(1 year, 5 months from now)

Drugs and Companies using CYANOCOBALAMIN ingredient

Market Authorisation Date: 31 January, 2005

Treatment: Cyanocobalamin administration through nasal infusion; Supplement for vitamin b12 deficiencies; Nasal administration of cyanocobalamin

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of NASCOBAL before it's patent expiration?
More Information on Dosage

95. List of Natesto drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8784882 ACERUS Controlled release delivery system for nasal applications and method of treatment
Feb, 2024

(1 year, 3 days from now)

US8877230 ACERUS Controlled release delivery system for nasal applications
Feb, 2024

(1 year, 3 days from now)

US8574622 ACERUS Controlled release delivery system for nasal applications
Feb, 2024

(1 year, 3 days from now)

US8784869 ACERUS Controlled release delivery system for nasal applications and methods of treatment
Feb, 2024

(1 year, 3 days from now)

Drugs and Companies using TESTOSTERONE ingredient

Market Authorisation Date: 28 May, 2014

Treatment: A method of testosterone replacement therapy comprising the step of nasally administering to a patient in need of such treatment an effective amount of testosterone gel formulation.; Nasal administration of a testosterone gel to a patient to treat the patient for a condition associated with a deficiency or absence of endogenous testosterone

Dosage: GEL, METERED;NASAL

More Information on Dosage

96. List of Ninlaro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8546608 TAKEDA PHARMS USA Proteasome inhibitors and methods of using the same
Aug, 2024

(1 year, 6 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9233115 TAKEDA PHARMS USA Proteasome inhibitors and methods of using the same
Aug, 2024

(1 year, 6 months from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 20, 2022

Drugs and Companies using IXAZOMIB CITRATE ingredient

Market Authorisation Date: 20 November, 2015

Treatment: Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy

Dosage: CAPSULE;ORAL

How can I launch a generic of NINLARO before it's patent expiration?
More Information on Dosage

97. List of Nocdurna drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7560429 FERRING PHARMS INC Orodispersible dosage forms of desmopressin acetate
Feb, 2024

(1 year, 1 day from now)

Drugs and Companies using DESMOPRESSIN ACETATE ingredient

Market Authorisation Date: 21 June, 2018

Treatment: Treatment of nocturia due to nocturnal polyuria in adults

Dosage: TABLET;SUBLINGUAL

More Information on Dosage

98. List of Noctiva drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7799761 SERENITY PHARMS LLC Pharmaceutical compositions including low dosages of desmopressin
Sep, 2024

(1 year, 7 months from now)

Drugs and Companies using DESMOPRESSIN ACETATE ingredient

Market Authorisation Date: 03 March, 2017

Treatment: NA

Dosage: SPRAY, METERED;NASAL

More Information on Dosage

99. List of Nourianz drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7541363 KYOWA KIRIN Microcrystal
Nov, 2024

(1 year, 9 months from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 27, 2024

Drugs and Companies using ISTRADEFYLLINE ingredient

NCE-1 date: August, 2023

Market Authorisation Date: 27 August, 2019

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

100. List of Nucynta Er drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8114383 COLLEGIUM PHARM INC Abuse-proofed dosage form
Oct, 2024

(1 year, 8 months from now)

Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient

Market Authorisation Date: 25 August, 2011

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of NUCYNTA ER before it's patent expiration?
More Information on Dosage

101. List of Nuplazid drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9566271 ACADIA PHARMS INC Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
Jan, 2024

(11 months from now)

US10028944 ACADIA PHARMS INC Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
Jan, 2024

(11 months from now)

US8618130 ACADIA PHARMS INC Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
Jan, 2024

(11 months from now)

US8921393 ACADIA PHARMS INC Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
Jan, 2024

(11 months from now)

Drugs and Companies using PIMAVANSERIN TARTRATE ingredient

Market Authorisation Date: 29 April, 2016

Treatment: Treatment of hallucinations and delusions associated with parkinson's disease psychosis; Treatment of psychosis or a symptom thereof; Treatment of a neurodegenerative disease or a symptom thereof

Dosage: TABLET;ORAL

How can I launch a generic of NUPLAZID before it's patent expiration?
More Information on Dosage

102. List of Nuvigil drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7297346

(Pediatric)

CEPHALON Pharmaceutical formulations of modafinil
May, 2024

(1 year, 3 months from now)

US7132570

(Pediatric)

CEPHALON Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil
Jun, 2024

(1 year, 4 months from now)

Drugs and Companies using ARMODAFINIL ingredient

Market Authorisation Date: 15 June, 2007

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of NUVIGIL before it's patent expiration?
More Information on Dosage

103. List of Nymalize drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8517997 AZURITY Dispenser for medicaments and method and apparatus for making same
May, 2024

(1 year, 3 months from now)

Drugs and Companies using NIMODIPINE ingredient

Market Authorisation Date: 10 May, 2013

Treatment: NA

Dosage: SOLUTION;ORAL

How can I launch a generic of NYMALIZE before it's patent expiration?
More Information on Dosage

104. List of Ofev drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7119093 BOEHRINGER INGELHEIM 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition
Feb, 2024

(1 year, 20 days from now)

Exclusivity Exclusivity Expiration
New Indication (I) Mar 9, 2023
Orphan Drug Exclusivity (ODE) Sep 6, 2026

Drugs and Companies using NINTEDANIB ESYLATE ingredient

Market Authorisation Date: 15 October, 2014

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of OFEV before it's patent expiration?
More Information on Dosage

105. List of Omegaven drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10350186 FRESENIUS KABI USA Treatment and prevention of liver disease associated with parenteral nutrition (PN)
Nov, 2024

(1 year, 9 months from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 27, 2023
Orphan Drug Exclusivity (ODE) Jul 27, 2025

Drugs and Companies using FISH OIL TRIGLYCERIDES ingredient

NCE-1 date: July, 2022

Market Authorisation Date: 27 July, 2018

Treatment: Treatment of parenteral nutrition-associated cholestasis in patients under the age of 12

Dosage: EMULSION;INTRAVENOUS

More Information on Dosage

106. List of Omidria drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8173707

(Pediatric)

RAYNER SURGICAL Ophthalmologic irrigation solutions and method
Jan, 2024

(11 months from now)

US8586633

(Pediatric)

RAYNER SURGICAL Ophthalmologic irrigation solutions and method
Jan, 2024

(11 months from now)

US9278101

(Pediatric)

RAYNER SURGICAL Ophthalmologic irrigation solutions and method
Jan, 2024

(11 months from now)

US9399040

(Pediatric)

RAYNER SURGICAL Ophthalmologic irrigation solutions and method
Jan, 2024

(11 months from now)

Drugs and Companies using KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 30 May, 2014

Treatment: NA

Dosage: SOLUTION;IRRIGATION

How can I launch a generic of OMIDRIA before it's patent expiration?
More Information on Dosage

107. List of Omontys drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7528104 TAKEDA PHARMS USA Peptides that bind to the erythropoietin receptor
May, 2024

(1 year, 3 months from now)

US7414105 TAKEDA PHARMS USA Peptides that bind to the erythropoietin receptor
May, 2024

(1 year, 3 months from now)

US7084245 TAKEDA PHARMS USA Peptides that bind to the erythropoietin receptor
May, 2024

(1 year, 3 months from now)

US7919118 TAKEDA PHARMS USA Spacer moiety for poly (ethylene glycol) modified peptide based compounds
May, 2024

(1 year, 3 months from now)

Drugs and Companies using PEGINESATIDE ACETATE ingredient

Market Authorisation Date: 27 March, 2012

Treatment: Treatment of anemia due to chronic kidney disease

Dosage: SOLUTION;INTRAVENOUS, SUBCUTANEOUS

More Information on Dosage

108. List of Onzetra Xsail drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9119932 CURRAX Nasal delivery device
Apr, 2024

(1 year, 2 months from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 27 January, 2016

Treatment: NA

Dosage: POWDER;NASAL

More Information on Dosage

109. List of Opana Er drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8114383 ENDO PHARMS Abuse-proofed dosage form
Aug, 2024

(1 year, 6 months from now)

Drugs and Companies using OXYMORPHONE HYDROCHLORIDE ingredient

Market Authorisation Date: 09 December, 2011

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

110. List of Oracea drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8709478 GALDERMA LABS LP Once daily formulations of tetracyclines
Apr, 2024

(1 year, 2 months from now)

US8394406 GALDERMA LABS LP Once daily formulations of tetracyclines
Apr, 2024

(1 year, 2 months from now)

US8470364 GALDERMA LABS LP Once daily formulations of tetracyclines
Apr, 2024

(1 year, 2 months from now)

US8394405 GALDERMA LABS LP Once daily formulations of tetracyclines
Apr, 2024

(1 year, 2 months from now)

Drugs and Companies using DOXYCYCLINE ingredient

Market Authorisation Date: 26 May, 2006

Treatment: Treatment of only inflammatory lesions (papules and pustules) of rosacea

Dosage: CAPSULE;ORAL

How can I launch a generic of ORACEA before it's patent expiration?
More Information on Dosage

111. List of Orenitram drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9050311 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
May, 2024

(1 year, 3 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9278901 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
May, 2024

(1 year, 3 months from now)

US8252839 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
May, 2024

(1 year, 3 months from now)

US9422223 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
May, 2024

(1 year, 3 months from now)

US7544713 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
Jul, 2024

(1 year, 5 months from now)

Exclusivity Exclusivity Expiration
New Indication (I) Oct 18, 2022
Orphan Drug Exclusivity (ODE) Oct 18, 2026

Drugs and Companies using TREPROSTINIL DIOLAMINE ingredient

Market Authorisation Date: 20 December, 2013

Treatment: Use of orenitram for the treatment of pulmonary arterial hypertension (pah) (who group 1).

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of ORENITRAM before it's patent expiration?
More Information on Dosage

112. List of Orgovyx drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8058280 MYOVANT SCIENCES Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof
Jan, 2024

(11 months from now)

US7300935 MYOVANT SCIENCES Thienopyrimidine compounds and use thereof
Jan, 2024

(11 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8735401 MYOVANT SCIENCES Thienopyrimidine compounds and use thereof
Feb, 2024

(1 year, 3 days from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 18, 2025

Drugs and Companies using RELUGOLIX ingredient

NCE-1 date: December, 2024

Market Authorisation Date: 18 December, 2020

Treatment: Treatment of adult patients with advanced prostate cancer that is sex-hormone-dependent

Dosage: TABLET;ORAL

More Information on Dosage

113. List of Oriahnn (copackaged) drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7419983 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods related thereto
Jul, 2024

(1 year, 5 months from now)

US7056927 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Sep, 2024

(1 year, 7 months from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 23, 2023
New Product (NP) May 29, 2023

Drugs and Companies using ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM ingredient

NCE-1 date: July, 2022

Market Authorisation Date: 29 May, 2020

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

114. List of Orilissa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7419983 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods related thereto
Jul, 2024

(1 year, 5 months from now)

US7056927 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Sep, 2024

(1 year, 7 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7176211 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Jul, 2024

(1 year, 5 months from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 23, 2023

Drugs and Companies using ELAGOLIX SODIUM ingredient

NCE-1 date: July, 2022

Market Authorisation Date: 23 July, 2018

Treatment: Management of moderate to severe pain associated with endometriosis

Dosage: TABLET;ORAL

How can I launch a generic of ORILISSA before it's patent expiration?
More Information on Dosage

115. List of Osphena drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8772353 DUCHESNAY Method for enhancing the bioavalability of ospemifene
Feb, 2024

(1 year, 12 days from now)

US8470890 DUCHESNAY Method for enhancing the bioavailability of ospemifene
Feb, 2024

(1 year, 12 days from now)

US9855224 DUCHESNAY Method for enhancing the bioavailability of ospemifene
Feb, 2024

(1 year, 12 days from now)

US9241915 DUCHESNAY Method for enhancing the bioavailability of ospemifene
Feb, 2024

(1 year, 12 days from now)

Exclusivity Exclusivity Expiration
New Indication (I) Jan 25, 2022

Drugs and Companies using OSPEMIFENE ingredient

Market Authorisation Date: 26 February, 2013

Treatment: Treatment of dyspareunia associated with menopause; Treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause; Treatment of vaginal symptoms of urogenital atrophy by orally administering ospemifene with food to enhance bioavailability of ospemifene

Dosage: TABLET;ORAL

How can I launch a generic of OSPHENA before it's patent expiration?
More Information on Dosage

116. List of Oxaydo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9492443 ZYLA Abuse deterrent compositions and methods of making same
May, 2024

(1 year, 3 months from now)

Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 17 June, 2011

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of OXAYDO before it's patent expiration?
More Information on Dosage

117. List of Ozempic drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7762994 NOVO Needle mounting system and a method for mounting a needle assembly
May, 2024

(1 year, 3 months from now)

Exclusivity Exclusivity Expiration
New Indication (I) Jan 16, 2023
New Chemical Entity Exclusivity (NCE) Dec 5, 2022
New Dosing Schedule (D) Mar 28, 2025

Drugs and Companies using SEMAGLUTIDE ingredient

NCE-1 date: December, 2021

Market Authorisation Date: 05 December, 2017

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of OZEMPIC before it's patent expiration?
More Information on Dosage

118. List of Ponvory drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE43728 JANSSEN PHARMS Thiazolidin-4-one derivatives
Nov, 2024

(1 year, 9 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9000018 JANSSEN PHARMS Thiazolidin-4-one-derivatives
Nov, 2024

(1 year, 9 months from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 18, 2026

Drugs and Companies using PONESIMOD ingredient

NCE-1 date: March, 2025

Market Authorisation Date: 18 March, 2021

Treatment: Reduction of circulating lymphocytes in treating relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults

Dosage: TABLET;ORAL

More Information on Dosage

119. List of Prevymis drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46791 MERCK SHARP DOHME Substituted dihydroquinazolines
May, 2024

(1 year, 3 months from now)

US8513255 MERCK SHARP DOHME Substituted dihydroquinazolines
May, 2024

(1 year, 3 months from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 8, 2024
New Chemical Entity Exclusivity (NCE) Nov 8, 2022

Drugs and Companies using LETERMOVIR ingredient

NCE-1 date: November, 2021

Market Authorisation Date: 08 November, 2017

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

120. List of Prezcobix drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8518987 JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Feb, 2024

(1 year, 15 days from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8518987

(Pediatric)

JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Aug, 2024

(1 year, 6 months from now)

Drugs and Companies using COBICISTAT; DARUNAVIR ingredient

Market Authorisation Date: 29 January, 2015

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of PREZCOBIX before it's patent expiration?